Cas no 124750-99-8 (Losartan Potassium)
Losartan Potassium Chemical and Physical Properties
Names and Identifiers
-
- Losartan Potassium
- Llosartan
- DuP-753 potassium
- Losartan
- Losartan (potassium salt)
- LOSARTAN MONOPOTASSIUM SALT
- Losartan Potassium (DuP 753)
- Losartan Potassium Salt
- LOSARTAN POTASSIUM, USP
- Potassium (2-butyl-4-chloro-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanolate
- 2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL MONOPOTASSIUM SALT
- Aradois
- COZAAR
- DUP 753
- dupont753
- Losartan (potassium)
- LOSARTAN POTASSIUM(SUBJECT TO PATENT FREE)
- mk-0954
- thanolpotassium
- 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]imidazole-5-methanol Potassium Salt
- NS00076270
- LOSARTAN POTASSIUM (USP MONOGRAPH)
- Ex-89
- Zaart
- losartanpotassium
- LOSARTAN POTASSIUM (MART.)
- LOSARTAN POTASSIUM [ORANGE BOOK]
- AB01275507-01
- LOSARTAN MONOPOTASSIUM SALT [MI]
- Losartan Potassium, Pharmaceutical Secondary Standard; Certified Reference Material
- CCG-100869
- Presartan-50
- AC-1072
- Losartan Potassium Tablets, 25 mg
- Losartan potassium, United States Pharmacopeia (USP) Reference Standard
- 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, monopotassium salt
- LOSARTAN POTASSIUM [USP-RS]
- LOSARTAN POTASSIUM [WHO-DD]
- 3ST302B24A
- E-3340
- MK 0954
- Potassium, Losartan
- HMS2051M12
- Losacor
- DuP753
- 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol, monopotassium salt
- ERYTHROPOIETIN
- Nu-Lotan
- MK 954
- LOSARTAN POTASSIUM (EP MONOGRAPH)
- Losartan potassium (USAN:USP)
- AKOS025310168
- LOSARTAN POTASSIUM (USP-RS)
- SR-05000001514
- D00357
- Salt, Losartan Monopotassium
- DTXCID1024209
- Losaprex
- MK-954
- Losatan Potassium
- LOSARTAN POTASSIUM [EP MONOGRAPH]
- Losartan Potassium Tablets, 100 mg
- losartan potassium tablet
- BCP05332
- Losartan potassium (JP17/USP)
- 2-Butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol, Monopotassium Salt
- Losortan Potassium
- SMR000469593
- Q27257991
- LOSARTAN POTASSIUM COMPONENT OF HYZAAR
- AKOS015955543
- BL164642
- HYZAAR COMPONENT LOSARTAN POTASSIUM
- Lifezar
- Losartan potassium [USAN]
- Du Pont 753
- Hyzaar
- MK0954
- CHEMBL995
- Lortaan
- L0232
- Lorzaan
- LOSARTAN POTASSIUM25 mg
- BCP29397
- Cozaar (TN)
- 124750-99-8
- LOSARTAN POTASSIUM [MART.]
- DU PONT-753
- LOSARTAN POTASSIUM [JAN]
- LOSARTAN POTASSIUM [HSDB]
- SR-05000001514-1
- potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
- Losartan Potassium is known as a potent, synthetic AT1 receptor antagonist.
- HMS2090O22
- Neo Lotan
- LOSARTAN POTASSIUM100 mg
- LOSARTAN POTASSIUM [USP MONOGRAPH]
- Ocsaar
- NC00119
- Losartan potassium [USAN:USP]
- [2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; potassium;Losartan potassium
- A805291
- FT-0625705
- Losacar
- L-158086
- HMS3393M12
- Losartan potassium; Potassium 5-[4'-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]biphenyl-2-yl]tetrazol-1-ide
- DTXSID3044209
- 2-Butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium
- 124750-99-8 (Ka+)
- HMS2235F20
- Tenopres
- EPO
- Monopotassium 5-((4'-(2-butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl)biphenyl-2-yl)-1H-tetrazol-1-ide
- Losartan Potatssium
- Losartan potassium,(S)
- Lotim
- Covance
- LOSARTAN POTASSIUM50 mg
- HMS3369F08
- Niten
- UNII-3ST302B24A
- Losartan potassium, analytical standard
- 2-Butyl-4-chloro-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)imidazole-5-methanol, monopotassium salt
- Losata
- Lorzaar
- Monopotassium Salt, Losartan
- SCHEMBL42079
- LOSARTAN POTASSIUM [VANDF]
- DuP-753
- Losartan potassium, European Pharmacopoeia (EP) Reference Standard
- Losartan Potassium Tablets, 50 mg
- MLS001401407
- potassium 5-(4'-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)biphenyl-2-yl)tetrazol-1-ide
- Tancin
- Losartan Potassium?
- potassium 5-(4'-((2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-1-ide
- FL24945
- Losartan potassium - Bio-X trade mark
- 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol potassium;Cozaar;MK-954
- 2-Butyl-4-chloro-1-2'-(1H-tetrazol-5yl)1,1'-biphenyl-4-ylmethyl-1H-imidazole-5-methanol potassium salt;Cozaar;MK-954
- 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, monopotassium salt
-
- MDL： MFCD02092704
- Inchi： 1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
- InChI Key： OXCMYAYHXIHQOA-UHFFFAOYSA-N
- SMILES： [K+].ClC1=C(CO)N(CC2C=CC(C3=CC=CC=C3C3=NN=N[N-]3)=CC=2)C(CCCC)=N1
Computed Properties
- Exact Mass: 460.11800
- Monoisotopic Mass: 460.118
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 31
- Rotatable Bond Count: 8
- Complexity: 526
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 2
- Topological Polar Surface Area: 77.7
Experimental Properties
- Color/Form: Bright yellow solid.
- Density: 0.986g/mLat 25°C(lit.)
- Melting Point: 268-271°C
- Boiling Point: 682°C at 760 mmHg
- Flash Point: 366.3 °C
- PSA: 89.61000
- LogP: 3.89590
- Solubility: Not determined
- Merck: 5583
Losartan Potassium Security Information
- Signal Word：Warning
- Hazard Statement： H315-H319-H335
- Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Hazard Category Code： 36/37/38
- Safety Instruction： S26; S36/37/39
- RTECS：NI6755100
-
Hazardous Material Identification：
- Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
- Risk Phrases：R36/37/38
Losartan Potassium Customs Data
- HS CODE：2933290090
- Customs Data：
China Customs Code:
2933290090Overview:
2933290090. Other compounds with non fused imidazole ring in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Losartan Potassium Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| MedChemExpress | HY-17512A-10mM*1mLinDMSO |
Losartan potassium |
124750-99-8 | 99.66% | 10mM*1mLinDMSO |
￥500 | 2022-05-18 | |
| MedChemExpress | HY-17512A-500mg |
Losartan potassium |
124750-99-8 | 99.91% | 500mg |
￥400 | 2024-04-20 | |
| MedChemExpress | HY-17512A-1g |
Losartan potassium |
124750-99-8 | 99.91% | 1g |
￥500 | 2024-04-20 | |
| MedChemExpress | HY-17512A-5g |
Losartan potassium |
124750-99-8 | 99.91% | 5g |
￥1200 | 2024-04-20 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L129227-5g |
Losartan Potassium |
124750-99-8 | ≥99% | 5g |
￥30.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L129227-1g |
Losartan Potassium |
124750-99-8 | ≥99% | 1g |
￥29.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L129227-100g |
Losartan Potassium |
124750-99-8 | ≥99% | 100g |
￥290.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L129227-25g |
Losartan Potassium |
124750-99-8 | ≥99% | 25g |
￥80.90 | 2023-09-02 | |
| AstaTech | 40296-5/G |
2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL MONOPOTASSIUM SALT |
124750-99-8 | 97% | 5g |
$69 | 2023-09-17 | |
| AstaTech | 40296-25/G |
2-BUTYL-4-CHLORO-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-METHANOL MONOPOTASSIUM SALT |
124750-99-8 | 97% | 25g |
$245 | 2023-09-17 |
Losartan Potassium Suppliers
Audited Supplier
Audited Supplier
Losartan Potassium Related Literature
-
Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
-
Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
-
Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
-
Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
Additional information on Losartan Potassium
Professional Introduction to Losartan Potassium (CAS No. 124750-99-8)
Losartan Potassium, a compound with the chemical name 4-[2'-(1H-tetrazol-5-yl)phenyl]imidazole-1-carboxylic acid, is a well-known pharmaceutical agent widely recognized for its therapeutic applications in the management of hypertension and heart failure. With the CAS number 124750-99-8, this compound has been extensively studied and utilized in clinical settings due to its potent angiotensin II receptor antagonist properties. This introduction delves into the pharmacological significance, recent research advancements, and clinical applications of Losartan Potassium.
The primary mechanism of action of Losartan Potassium revolves around its ability to block the binding of angiotensin II to its AT1 receptors, thereby preventing the vasoconstriction and aldosterone secretion that contribute to hypertension. This mechanism has been a cornerstone in the treatment of cardiovascular diseases, making Losartan Potassium a staple in modern pharmacotherapy. The compound's efficacy and safety have been supported by numerous clinical trials, which have demonstrated its effectiveness in reducing blood pressure and improving renal function in patients with various cardiovascular conditions.
Recent research has expanded the understanding of Losartan Potassium beyond its traditional applications. Studies have begun to explore its potential role in mitigating the progression of chronic kidney disease (CKD), particularly in patients with diabetes. The ability of Losartan Potassium to reduce proteinuria and slow down the decline in glomerular filtration rate has been a significant finding. This has opened up new avenues for therapeutic intervention in CKD management.
In addition to its cardiovascular benefits, Losartan Potassium has shown promise in neuroprotective therapies. Emerging evidence suggests that the compound may have neuroprotective effects, potentially making it a candidate for treating neurological disorders such as Alzheimer's disease and stroke. The exact mechanisms behind these effects are still under investigation, but initial findings are encouraging. The compound's ability to cross the blood-brain barrier and exert its effects within the central nervous system is an area of active research interest.
The pharmacokinetics of Losartan Potassium are another critical aspect that has been thoroughly examined. The compound is rapidly absorbed after oral administration, with peak plasma concentrations typically observed within one to two hours. Its bioavailability is high, and it undergoes extensive metabolism primarily via cytochrome P450 enzymes. Understanding these pharmacokinetic properties is essential for optimizing dosing regimens and minimizing potential drug interactions.
One of the notable features of Losartan Potassium is its long half-life, which allows for once-daily dosing. This convenience has improved patient compliance and made it a preferred choice for long-term management of hypertension and heart failure. The extended half-life is attributed to its slow elimination from the body, ensuring sustained therapeutic levels over an extended period.
The safety profile of Losartan Potassium is well-documented, with adverse effects generally being mild and transient. Common side effects include dizziness, cough, hyperkalemia, and fatigue. However, rare but serious adverse effects such as angioedema have been reported, necessitating careful monitoring in patients with a history of angioedema or those taking other angiotensin-converting enzyme (ACE) inhibitors.
Recent clinical trials have further reinforced the efficacy of Losartan Potassium in diverse patient populations. A study published in the *Journal of Hypertension* highlighted its effectiveness in reducing cardiovascular mortality in patients with hypertension and diabetes. Another trial demonstrated its benefits in improving quality of life measures among elderly patients with heart failure. These findings underscore the compound's versatility and broad applicability across different clinical scenarios.
The role of Losartan Potassium in combination therapy cannot be overstated. Its use alongside other antihypertensive agents has been shown to provide synergistic benefits, particularly in patients with resistant hypertension or those at high risk for cardiovascular complications. The combination approach not only enhances therapeutic outcomes but also allows for personalized treatment strategies tailored to individual patient needs.
Future research directions for Losartan Potassium are multifaceted, focusing on exploring new therapeutic applications and optimizing existing ones. Investigating its potential role in cancer therapy is one such area that has garnered attention recently. Preclinical studies suggest that Losartan Potassium may inhibit tumor growth and angiogenesis by modulating various signaling pathways involved in cancer progression.
The compound's anti-inflammatory properties are also being explored as a potential therapeutic strategy for chronic inflammatory diseases such as rheumatoid arthritis and psoriasis. By targeting key inflammatory pathways, Losartan Potassium may offer a novel approach to managing these conditions without the side effects associated with traditional anti-inflammatory drugs.
In conclusion, Losartan Potassium (CAS No. 124750-99-8) remains a cornerstone in modern pharmacotherapy for managing hypertension and heart failure. Its potent angiotensin II receptor antagonist activity, combined with recent findings on its potential roles in neuroprotection, chronic kidney disease management, and even cancer therapy, highlights its multifaceted therapeutic applications. As research continues to uncover new uses for this compound, it is likely to remain an essential medication in the armamentarium of healthcare professionals worldwide.
124750-99-8 (Losartan Potassium) Related Products
- 114798-26-4(Losartan)
- 11096-26-7(Losartan potassium)
- 1030936-74-3(Losartan-d3)
- 124750-92-1(Losartan Carboxylic Acid)
- 1189729-40-5(Losartan-d3 Carboxylic Acid)
- 1030937-27-9(Losartan-d)
- 141675-57-2(ω-1-Hydroxy Losartan)
- 141675-59-4(ω-3-Hydroxy Losartan)
- 1246820-62-1(Losartan-d)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
